- Developing revolutionary injectable CBD delivery system that facilitates targeted, controlled administration of cannabinoids into the bloodstream
- Strategic partnership with Hebrew University to study Liposome Platform Technology
- Targeting commercial sales in 2020
What InnoCan Pharma does:
Very few active ingredients of CBD are absorbed into the body. At best, around 15% of CBD oil is absorbed when taken orally, but the average is closer to between 5% and 10%. The culprit? Our liver enzymes, which destroy over 80% of the essential components.
InnoCan is developing a revolutionary injectable CBD delivery system that facilitates targeted, controlled administration of cannabinoids into the bloodstream. The Liposome Platform Technology (LPT) is being developed in conjunction with the Hebrew University in Jerusalem by a team with serious experience in liposomal delivery systems.
LPT can enable increased bioavailability, targeted towards a specific organ or body part, with precise time and dosage control. InnoCan holds a globally exclusive license to commercialize the research results and products that stem from the technology.
According to the Israeli company, LPT has the potential to become a licensing platform to large pharmaceutical companies either for CBD dosage or their own specific needs.
InnoCan also boasts a line of over-the-counter topical CBD creams that work for both pain relief and psoriasis, both of which are multibillion-dollar industries. In addition, the firm markets a line of premium CBD-infused derma cosmetic products distributed throughout the UK and Ireland.
With around 144 million shares outstanding and a market capitalization of about C$14 million, InnoCan is poised for a breakout year as it commercializes its unique technology.
How is it doing:
InnoCan is the first Israeli firm to do an initial public offering (IPO) with a full prospectus on the Canadian Securities Exchange, making it somewhat of a pioneer in the financial world.
Initial results from LPT’s research are positive for loading the liposome with a therapeutic dose of CBS and controlling the release of the active ingredients.
The controlled release of CBD or other cannabinoids from the liposomes may allow continuous exposure of the patient to the cannabinoid and decreases the variations of CBD concentration in the blood caused by food intake or other physiological conditions.
Moreover, through injection of loaded liposomes, a greater portion of intact CBD can reach its target site, decreasing the total amount of CBD needed to achieve the desired therapeutic effect. The use of the technology is versatile and may be tailored to the development of different cannabinoids.
On the commercial front, InnoCan signed an agreement with Active Therapeutics Ltd to distribute its CBD-based Derma Cosmetic products in the UK and Ireland. Active Therapeutics has vast experience in pharmaceuticals and healthcare, including the brand portfolios of Merck & Co Inc (NYSE:MRK) and AstraZeneca PLC (LON:AZN) (NYSE:AZN).
At the beginning of February, InnoCan filed a new patent application for a cannabis-based formula targeting the pain, swelling and inflammation associated with haemorrhoids.
With the patent filing, the company is expanding its intellectual property estate for cannabis-integrated pain relief products as a source of potentially exciting breakthroughs in pain therapy, as well as an engine for additional products.
- Targeting commercial sales in 2Q 2020
- Currently manufacturing its Derma Cosmetic products, with nine items expected to be available by March 2020
- Signed distribution agreements with potential retailers both online and offline
What the boss says:
InnoCan's CEO Iris Bincovich recently commented on the encouraging results produced from the LPT study with Hebrew University, saying that it opens up a number of options for the firm.
"These positive first stage results are a powerful demonstration of the value of our partnership with Hebrew University,” Bincovich said. “Continued test success would provide InnoCan with numerous commercial prospects. We anticipate the completion of the next development stage, within 18 to 24 months."
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas